1. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
by Alexander Röth, Andreas Hüttmann, Russell P. Rother, Ulrich Dührsen, and Thomas Philipp
Blood
Volume 113(16):
April 16, 2009
©2009 by American Society of Hematology

2. Effect of eculizumab in a patient with cold agglutinin disease.
Effect of eculizumab in a patient with cold agglutinin disease. Levels of hemolysis (as measured by LDH, ○) and anemia (hemoglobin, ▲) were documented in the year before and after initiation of eculizumab treatment. Transfusion episodes (↑) are also shown.
Alexander Röth et al. Blood 2009;113:
©2009 by American Society of Hematology